Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 353 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer August 28, 2020 Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... November 28, 2024 The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... July 16, 2018 What Is Mindfulness and How Can It Help People With Cancer? July 5, 2022 Load more HOT NEWS Patient Guide on Cancer Pain Management Now Available Also in French Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... Keto Molecule Offers Clue for Preventing Colorectal Cancer EMA Recommends Granting a Marketing Authorisation for Generic Sunitinib
